<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03703336</url>
  </required_header>
  <id_info>
    <org_study_id>CVIA 068</org_study_id>
    <secondary_id>VX.2018.05</secondary_id>
    <nct_id>NCT03703336</nct_id>
  </id_info>
  <brief_title>Phase III Study of Liquid Formulation of ROTAVIN</brief_title>
  <official_title>A Phase III, Randomized, Partially Double- Blind, Active Control Study to Compare the Immunogenicity and Safety of a Liquid Formulation of ROTAVIN With the Currently Licensed Frozen Formulation of the Vaccine (ROTAVIN-M1), in Healthy Vietnamese Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Research and Production of Vaccines and Biologicals, Vietnam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Hygiene and Epidemiology, Vietnam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Research and Production of Vaccines and Biologicals, Vietnam</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to demonstrate non-inferiority in the immunogenicity of the liquid&#xD;
      formulation of ROTAVIN in comparison to currently licensed frozen formulation of the vaccine&#xD;
      (ROTAVIN-M1), 28 days after the second vaccination when administered as two dose series&#xD;
      starting at 2-3 months of age.&#xD;
&#xD;
      The study will also assess the reactogenicity of the vaccine 7 days after each vaccination&#xD;
      and safety from first vaccination up to 4 weeks after the last vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed as a phase III, randomized, partially double-blinded, active controlled&#xD;
      study with two groups of infants receiving vaccines at the ratio of 2:1 (liquid formulation&#xD;
      of ROTAVIN to frozen formulation ROTAVIN-M1), to compare their immunogenicity and safety. Two&#xD;
      doses of vaccine will be administered 8 weeks apart with the first vaccine administration&#xD;
      between 60-91 days of age. All childhood vaccines as per the Expanded Program for&#xD;
      Immunization of the Government of Vietnam (including Diphtheria, Tetanus, Pertussis,&#xD;
      Haemophilus influenzae type b and Hepatitis B vaccine (DTwPHib-HepB), and Oral Polio Vaccine&#xD;
      at at 2, 3 and 4 months of age) will be allowed as per the immunization schedule.&#xD;
&#xD;
      Active surveillance for vaccine reactogenicity (solicited reactions) over the 7-day period&#xD;
      after each vaccination, unsolicited adverse events (AEs) for 4 weeks after each vaccination&#xD;
      and serious adverse events (SAEs) including intussusception over the period between first&#xD;
      vaccination and four weeks after the last vaccination will be conducted for all infants.&#xD;
&#xD;
      This trial will generate immunogenicity and safety data which would be submitted to Ministry&#xD;
      of Health in Vietnam for license of new formulation of ROTAVIN vaccine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2019</start_date>
  <completion_date type="Actual">January 8, 2020</completion_date>
  <primary_completion_date type="Actual">January 8, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible infants will be randomized to receive either ROTAVIN or ROTAVIN-M1 vaccines in the ratio of 2:1.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) of Serum Anti-rotavirus Immunoglobulin A (IgA) Antibodies 28 Days After Second Vaccination</measure>
    <time_frame>Day 85 (28 days after the second vaccination)</time_frame>
    <description>Serum anti-rotavirus IgA antibodies were measured using a validated enzyme linked immunosorbent assay (ELISA) at the Cincinnati Children's Hospital Medical Center (CCHMC), Division of Infectious Diseases in Cincinnati, Ohio USA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Reactions Within 7 Days of Vaccination</measure>
    <time_frame>7 days after each vaccination (Days 1 to 8 and 57 to 64)</time_frame>
    <description>Solicited post-vaccination reactogenicity included fever, diarrhea, vomiting, decreased appetite, irritability, and decreased activity level during the seven-day period after each vaccination. Parents were asked to record reactions on a post-immunization diary card.&#xD;
Solicited reactions were graded for severity on a scale from mild to severe based on the level of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seroconversion 28 Days After the Second Vaccination</measure>
    <time_frame>28 days after the second vaccination (Day 85)</time_frame>
    <description>Seroconversion is defined as a post-vaccination serum anti-rotavirus IgA antibody concentration of at least 20 U/mL if the baseline concentration was &lt; 20 U/mL or a post- vaccination serum anti-rotavirus IgA antibody concentration of ≥ 4-fold baseline level if the baseline concentration was ≥ 20 U/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Seropositivity at Baseline and 28 Days After the Second Vaccination</measure>
    <time_frame>Baseline (Day 1) and at 28 days after the second vaccination (Day 85)</time_frame>
    <description>Seropositivity is defined as serum IgA antibody concentration ≥ 20 U/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Immediate Adverse Events (AEs)</measure>
    <time_frame>Within 30 minutes after each vaccination on Day 1 and Day 57</time_frame>
    <description>After each vaccination participants were observed at the clinic site for at least 30 minutes to check for any immediate AEs including episodes of vomiting and allergic reaction to vaccine. Immediate AEs include all reactions that occurred within 30 minutes of each vaccination.&#xD;
Reactions were graded for severity per the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1, of the US National Institute of Health:&#xD;
Grade 1: Mild symptoms causing no or minimal interference with usual social &amp; functional activities; intervention not indicated.&#xD;
Grade 2: Moderate symptoms causing greater than minimal interference with usual activities; intervention indicated.&#xD;
Grade 3: Severe symptoms causing inability to perform usual activities; intervention or hospitalization indicated.&#xD;
Grade 4: Potentially life-threatening symptoms; intervention indicated to prevent permanent impairment, persistent disability, or death&#xD;
Grade 5: Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events</measure>
    <time_frame>From vaccination through 28 days after each dose (Days 1 to 28 and 57 to 85)</time_frame>
    <description>An unsolicited AE was any AE that occurred after vaccination, whether or not deemed &quot;related&quot; to the product, that was not solicited, or, any solicited reaction that started after 7 days post-vaccination. Severity of unsolicited AEs was graded per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1.&#xD;
Grade 1: Mild symptoms causing no or minimal interference with usual social &amp; functional activities; intervention not indicated&#xD;
Grade 2: Moderate symptoms causing greater than minimal interference with usual activities; intervention indicated&#xD;
Grade 3: Severe symptoms causing inability to perform usual activities; intervention or hospitalization indicated&#xD;
Grade 4: Potentially life-threatening symptoms; intervention indicated to prevent permanent impairment, persistent disability, or death&#xD;
Grade 5: Death&#xD;
The clinician classified the causality of each AE as related if there was reasonable possibility that the product caused the event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events Including Intussusception</measure>
    <time_frame>From first vaccination through 28 days after the last vaccination; 85 days</time_frame>
    <description>All Serious adverse events (SAEs), including cases of intussusception, were recorded at all time points between first vaccination and last visit. An SAE was defined as any untoward medical occurrence that:&#xD;
Resulted in death,&#xD;
Was life threatening,&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization,&#xD;
Resulted in persistent or significant disability / incapacity,&#xD;
Was a congenital anomaly or a birth defect,&#xD;
Medically important event&#xD;
Investigator-confirmed cases of intussusception also qualified as an SAE in this study. Intussusception is the infolding (telescoping) of one segment of the intestine within another, usually resulting in a blockage of the intestine.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">825</enrollment>
  <condition>Diarrhea</condition>
  <condition>Diarrhea Rotavirus</condition>
  <arm_group>
    <arm_group_label>ROTAVIN Liquid Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROTAVIN-M1 Frozen Formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ROTAVIN (liquid formulation)</intervention_name>
    <description>Live attenuated human rotavirus vaccine containing ≥ 2x10^6 plaque forming units (PFU) of strain G1P[8] per dose of 2 mL.</description>
    <arm_group_label>ROTAVIN Liquid Formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ROTAVIN-M1 (frozen formulation)</intervention_name>
    <description>Live attenuated human rotavirus vaccine containing ≥ 2x10^6 PFU of strain G1P[8] per dose of 2 mL.</description>
    <arm_group_label>ROTAVIN-M1 Frozen Formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy infants as established by medical history and clinical examination before&#xD;
             entering the study.&#xD;
&#xD;
          2. Age: 60-91 days (both days inclusive) at the time of enrollment.&#xD;
&#xD;
          3. Parental/legally acceptable representative ability and willingness to provide written&#xD;
             informed consent.&#xD;
&#xD;
          4. Parent/legally acceptable representative who intends to remain in the area with the&#xD;
             child during the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of diarrhea or vomiting in the previous 72 hours or on the day of enrollment&#xD;
             (temporary exclusion).&#xD;
&#xD;
          2. Presence of fever on the day of enrollment (temporary exclusion).&#xD;
&#xD;
          3. Acute disease at the time of enrollment (temporary exclusion).&#xD;
&#xD;
          4. Concurrent participation in another clinical trial at any point throughout the entire&#xD;
             time frame for this study.&#xD;
&#xD;
          5. Presence of significant malnutrition (weight-for-height z-score &lt; -3 SD median)&#xD;
&#xD;
          6. Presence of any systemic disorder (cardiovascular, pulmonary, hepatic, renal,&#xD;
             gastrointestinal, hematological, endocrine, immunological, dermatological,&#xD;
             neurological, cancer, or autoimmune disease) as determined by medical history and / or&#xD;
             physical examination which would compromise the participant's health or is likely to&#xD;
             result in nonconformance to the protocol.&#xD;
&#xD;
          7. History of congenital abdominal disorders, intussusception, or abdominal surgery.&#xD;
&#xD;
          8. Known or suspected impairment of immunological function based on medical history and&#xD;
             physical examination.&#xD;
&#xD;
          9. Household contact with an immunosuppressed individual or pregnant woman.&#xD;
&#xD;
         10. Prior receipt of rotavirus or an intent to receive this vaccine from outside of the&#xD;
             study center during study participation.&#xD;
&#xD;
         11. Prior receipt of Expanded Program on Immunization (EPI) vaccination during past 7 days&#xD;
             or plan to receive them within next 7 days.&#xD;
&#xD;
         12. A known sensitivity or allergy to any components of the study vaccine.&#xD;
&#xD;
         13. History of allergy to antibiotic kanamycin.&#xD;
&#xD;
         14. Clinically detectable significant congenital or genetic defect.&#xD;
&#xD;
         15. History of persistent diarrhea (defined as diarrhea that lasts 14 days or longer).&#xD;
&#xD;
         16. Receipt of immunoglobulin therapy and / or blood products since birth or planned&#xD;
             administration during the study period.&#xD;
&#xD;
         17. History of chronic administration (defined as more than 14 days) of immunosuppressants&#xD;
             including corticosteroids. Infants on inhaled or topical steroids may be permitted to&#xD;
             participate in the study.&#xD;
&#xD;
         18. Any medical condition in the parent/legally acceptable representative or infant which,&#xD;
             in the judgment of the Investigator, would interfere with or serves as a&#xD;
             contraindication to protocol adherence.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Days</minimum_age>
    <maximum_age>91 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niraj Rathi, MD</last_name>
    <role>Study Director</role>
    <affiliation>PATH India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CDC Nam Dinh</name>
      <address>
        <city>Nam Dinh</city>
        <zip>10000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CDC Quang Ninh</name>
      <address>
        <city>Quang Ninh</city>
        <zip>10000</zip>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 9, 2018</study_first_submitted>
  <study_first_submitted_qc>October 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2018</study_first_posted>
  <results_first_submitted>January 5, 2021</results_first_submitted>
  <results_first_submitted_qc>January 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2021</results_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ROTAVIN</keyword>
  <keyword>Rotavirus vaccine</keyword>
  <keyword>Rotavirus</keyword>
  <keyword>Diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03703336/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 12, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03703336/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted by the National Institute of Hygiene and Epidemiology (NIHE) at 12 health centers in one district in the Nam Dinh province and at 12 health centers in one district in the Quang Ninh province in Vietnam.</recruitment_details>
      <pre_assignment_details>Infants were allocated to one of the two groups at a ratio of 2:1 to receive either the ROTAVIN liquid formulation or the frozen formulation ROTAVIN-M1.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ROTAVIN Liquid Formulation</title>
          <description>Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
        </group>
        <group group_id="P2">
          <title>ROTAVIN-M1 Frozen Formulation</title>
          <description>Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="552"/>
                <participants group_id="P2" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="552"/>
                <participants group_id="P2" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="518"/>
                <participants group_id="P2" count="263"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="551"/>
                <participants group_id="P2" count="274"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="514"/>
                <participants group_id="P2" count="259"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Parent withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migration</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population, as treated</population>
      <group_list>
        <group group_id="B1">
          <title>ROTAVIN Liquid Formulation</title>
          <description>Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
        </group>
        <group group_id="B2">
          <title>ROTAVIN-M1 Frozen Formulation</title>
          <description>Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="551"/>
            <count group_id="B2" value="274"/>
            <count group_id="B3" value="825"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.7" spread="8.63"/>
                    <measurement group_id="B2" value="75.2" spread="9.15"/>
                    <measurement group_id="B3" value="74.8" spread="8.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="420"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="275"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Vietnamese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="551"/>
                    <measurement group_id="B2" value="274"/>
                    <measurement group_id="B3" value="825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Province</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Nam Dinh province</title>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="375"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Quang Ninh province</title>
                  <measurement_list>
                    <measurement group_id="B1" value="300"/>
                    <measurement group_id="B2" value="150"/>
                    <measurement group_id="B3" value="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) of Serum Anti-rotavirus Immunoglobulin A (IgA) Antibodies 28 Days After Second Vaccination</title>
        <description>Serum anti-rotavirus IgA antibodies were measured using a validated enzyme linked immunosorbent assay (ELISA) at the Cincinnati Children's Hospital Medical Center (CCHMC), Division of Infectious Diseases in Cincinnati, Ohio USA.</description>
        <time_frame>Day 85 (28 days after the second vaccination)</time_frame>
        <population>Immunogenicity assays were conducted on the subset of participants enrolled at Quang Ninh.&#xD;
The Per-Protocol (PP) population was defined as randomized participants who received a study vaccination, provided at least one evaluable serum sample, and who correctly received study vaccine per randomization with no major protocol deviations that were determined to potentially interfere with the immunogenicity assessment of the study vaccines.</population>
        <group_list>
          <group group_id="O1">
            <title>ROTAVIN Liquid Formulation</title>
            <description>Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
          <group group_id="O2">
            <title>ROTAVIN-M1 Frozen Formulation</title>
            <description>Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) of Serum Anti-rotavirus Immunoglobulin A (IgA) Antibodies 28 Days After Second Vaccination</title>
          <description>Serum anti-rotavirus IgA antibodies were measured using a validated enzyme linked immunosorbent assay (ELISA) at the Cincinnati Children's Hospital Medical Center (CCHMC), Division of Infectious Diseases in Cincinnati, Ohio USA.</description>
          <population>Immunogenicity assays were conducted on the subset of participants enrolled at Quang Ninh.&#xD;
The Per-Protocol (PP) population was defined as randomized participants who received a study vaccination, provided at least one evaluable serum sample, and who correctly received study vaccine per randomization with no major protocol deviations that were determined to potentially interfere with the immunogenicity assessment of the study vaccines.</population>
          <units>U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.25" lower_limit="40.59" upper_limit="57.37"/>
                    <measurement group_id="O2" value="35.04" lower_limit="27.34" upper_limit="44.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>If the lower limit of the 95% confidence interval (CI) of the ratio of GMCs between the ROTAVIN and ROTAVIN-M1 groups were to be larger than 1/2, ROTAVIN was considered to be non-inferior to the licensed frozen formulation of the vaccine (ROTAVIN-M1).</non_inferiority_desc>
            <param_type>GMC Ratio</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.02</ci_lower_limit>
            <ci_upper_limit>1.86</ci_upper_limit>
            <estimate_desc>Log10-transformed IgA concentrations were used to construct a 2-sided 95% CI for the mean difference between the arms using t-distribution. The mean difference and 95% CI were exponentiated to obtain the GMC ratio and corresponding 95% CI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Reactions Within 7 Days of Vaccination</title>
        <description>Solicited post-vaccination reactogenicity included fever, diarrhea, vomiting, decreased appetite, irritability, and decreased activity level during the seven-day period after each vaccination. Parents were asked to record reactions on a post-immunization diary card.&#xD;
Solicited reactions were graded for severity on a scale from mild to severe based on the level of symptoms.</description>
        <time_frame>7 days after each vaccination (Days 1 to 8 and 57 to 64)</time_frame>
        <population>Safety population, as treated</population>
        <group_list>
          <group group_id="O1">
            <title>ROTAVIN Liquid Formulation</title>
            <description>Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
          <group group_id="O2">
            <title>ROTAVIN-M1 Frozen Formulation</title>
            <description>Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Reactions Within 7 Days of Vaccination</title>
          <description>Solicited post-vaccination reactogenicity included fever, diarrhea, vomiting, decreased appetite, irritability, and decreased activity level during the seven-day period after each vaccination. Parents were asked to record reactions on a post-immunization diary card.&#xD;
Solicited reactions were graded for severity on a scale from mild to severe based on the level of symptoms.</description>
          <population>Safety population, as treated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="551"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased activity level</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seroconversion 28 Days After the Second Vaccination</title>
        <description>Seroconversion is defined as a post-vaccination serum anti-rotavirus IgA antibody concentration of at least 20 U/mL if the baseline concentration was &lt; 20 U/mL or a post- vaccination serum anti-rotavirus IgA antibody concentration of ≥ 4-fold baseline level if the baseline concentration was ≥ 20 U/mL.</description>
        <time_frame>28 days after the second vaccination (Day 85)</time_frame>
        <population>Immunogenicity assays were conducted on the subset of participants enrolled at Quang Ninh.&#xD;
The Per-Protocol (PP) population was defined as randomized participants who received a study vaccination, provided at least one evaluable serum sample, and who correctly received study vaccine per randomization with no major protocol deviations that were determined to potentially interfere with the immunogenicity assessment of the study vaccines.</population>
        <group_list>
          <group group_id="O1">
            <title>ROTAVIN Liquid Formulation</title>
            <description>Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
          <group group_id="O2">
            <title>ROTAVIN-M1 Frozen Formulation</title>
            <description>Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seroconversion 28 Days After the Second Vaccination</title>
          <description>Seroconversion is defined as a post-vaccination serum anti-rotavirus IgA antibody concentration of at least 20 U/mL if the baseline concentration was &lt; 20 U/mL or a post- vaccination serum anti-rotavirus IgA antibody concentration of ≥ 4-fold baseline level if the baseline concentration was ≥ 20 U/mL.</description>
          <population>Immunogenicity assays were conducted on the subset of participants enrolled at Quang Ninh.&#xD;
The Per-Protocol (PP) population was defined as randomized participants who received a study vaccination, provided at least one evaluable serum sample, and who correctly received study vaccine per randomization with no major protocol deviations that were determined to potentially interfere with the immunogenicity assessment of the study vaccines.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" lower_limit="64.54" upper_limit="75.82"/>
                    <measurement group_id="O2" value="64.4" lower_limit="55.75" upper_limit="72.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>6.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.57</ci_lower_limit>
            <ci_upper_limit>15.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Seropositivity at Baseline and 28 Days After the Second Vaccination</title>
        <description>Seropositivity is defined as serum IgA antibody concentration ≥ 20 U/mL</description>
        <time_frame>Baseline (Day 1) and at 28 days after the second vaccination (Day 85)</time_frame>
        <population>Immunogenicity assays were conducted on the subset of participants enrolled at Quang Ninh.&#xD;
The Per-Protocol (PP) population was defined as randomized participants who received a study vaccination, provided at least one evaluable serum sample, and who correctly received study vaccine per randomization with no major protocol deviations that were determined to potentially interfere with the immunogenicity assessment of the study vaccines.</population>
        <group_list>
          <group group_id="O1">
            <title>ROTAVIN Liquid Formulation</title>
            <description>Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
          <group group_id="O2">
            <title>ROTAVIN-M1 Frozen Formulation</title>
            <description>Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Seropositivity at Baseline and 28 Days After the Second Vaccination</title>
          <description>Seropositivity is defined as serum IgA antibody concentration ≥ 20 U/mL</description>
          <population>Immunogenicity assays were conducted on the subset of participants enrolled at Quang Ninh.&#xD;
The Per-Protocol (PP) population was defined as randomized participants who received a study vaccination, provided at least one evaluable serum sample, and who correctly received study vaccine per randomization with no major protocol deviations that were determined to potentially interfere with the immunogenicity assessment of the study vaccines.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="267"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" lower_limit="0.01" upper_limit="2.07"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.00" upper_limit="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8" lower_limit="64.93" upper_limit="76.17"/>
                    <measurement group_id="O2" value="64.4" lower_limit="55.75" upper_limit="72.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage Difference on Day 1</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.40</ci_lower_limit>
            <ci_upper_limit>2.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percentage Difference on Day 85</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Percentage Difference</param_type>
            <param_value>6.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.19</ci_lower_limit>
            <ci_upper_limit>16.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Immediate Adverse Events (AEs)</title>
        <description>After each vaccination participants were observed at the clinic site for at least 30 minutes to check for any immediate AEs including episodes of vomiting and allergic reaction to vaccine. Immediate AEs include all reactions that occurred within 30 minutes of each vaccination.&#xD;
Reactions were graded for severity per the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1, of the US National Institute of Health:&#xD;
Grade 1: Mild symptoms causing no or minimal interference with usual social &amp; functional activities; intervention not indicated.&#xD;
Grade 2: Moderate symptoms causing greater than minimal interference with usual activities; intervention indicated.&#xD;
Grade 3: Severe symptoms causing inability to perform usual activities; intervention or hospitalization indicated.&#xD;
Grade 4: Potentially life-threatening symptoms; intervention indicated to prevent permanent impairment, persistent disability, or death&#xD;
Grade 5: Death</description>
        <time_frame>Within 30 minutes after each vaccination on Day 1 and Day 57</time_frame>
        <population>Safety population, as treated</population>
        <group_list>
          <group group_id="O1">
            <title>ROTAVIN Liquid Formulation</title>
            <description>Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
          <group group_id="O2">
            <title>ROTAVIN-M1 Frozen Formulation</title>
            <description>Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immediate Adverse Events (AEs)</title>
          <description>After each vaccination participants were observed at the clinic site for at least 30 minutes to check for any immediate AEs including episodes of vomiting and allergic reaction to vaccine. Immediate AEs include all reactions that occurred within 30 minutes of each vaccination.&#xD;
Reactions were graded for severity per the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1, of the US National Institute of Health:&#xD;
Grade 1: Mild symptoms causing no or minimal interference with usual social &amp; functional activities; intervention not indicated.&#xD;
Grade 2: Moderate symptoms causing greater than minimal interference with usual activities; intervention indicated.&#xD;
Grade 3: Severe symptoms causing inability to perform usual activities; intervention or hospitalization indicated.&#xD;
Grade 4: Potentially life-threatening symptoms; intervention indicated to prevent permanent impairment, persistent disability, or death&#xD;
Grade 5: Death</description>
          <population>Safety population, as treated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="551"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any immediate adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate AEs occurring after dose 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate AEs occurring after dose 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pyrexia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild Immediate AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Immediate AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Immediate AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-threatening Immediate AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Unsolicited Adverse Events</title>
        <description>An unsolicited AE was any AE that occurred after vaccination, whether or not deemed &quot;related&quot; to the product, that was not solicited, or, any solicited reaction that started after 7 days post-vaccination. Severity of unsolicited AEs was graded per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1.&#xD;
Grade 1: Mild symptoms causing no or minimal interference with usual social &amp; functional activities; intervention not indicated&#xD;
Grade 2: Moderate symptoms causing greater than minimal interference with usual activities; intervention indicated&#xD;
Grade 3: Severe symptoms causing inability to perform usual activities; intervention or hospitalization indicated&#xD;
Grade 4: Potentially life-threatening symptoms; intervention indicated to prevent permanent impairment, persistent disability, or death&#xD;
Grade 5: Death&#xD;
The clinician classified the causality of each AE as related if there was reasonable possibility that the product caused the event.</description>
        <time_frame>From vaccination through 28 days after each dose (Days 1 to 28 and 57 to 85)</time_frame>
        <population>Safety population, as treated</population>
        <group_list>
          <group group_id="O1">
            <title>ROTAVIN Liquid Formulation</title>
            <description>Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
          <group group_id="O2">
            <title>ROTAVIN-M1 Frozen Formulation</title>
            <description>Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Adverse Events</title>
          <description>An unsolicited AE was any AE that occurred after vaccination, whether or not deemed &quot;related&quot; to the product, that was not solicited, or, any solicited reaction that started after 7 days post-vaccination. Severity of unsolicited AEs was graded per the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1.&#xD;
Grade 1: Mild symptoms causing no or minimal interference with usual social &amp; functional activities; intervention not indicated&#xD;
Grade 2: Moderate symptoms causing greater than minimal interference with usual activities; intervention indicated&#xD;
Grade 3: Severe symptoms causing inability to perform usual activities; intervention or hospitalization indicated&#xD;
Grade 4: Potentially life-threatening symptoms; intervention indicated to prevent permanent impairment, persistent disability, or death&#xD;
Grade 5: Death&#xD;
The clinician classified the causality of each AE as related if there was reasonable possibility that the product caused the event.</description>
          <population>Safety population, as treated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="551"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any unsolicited adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-threatening adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related to study vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unrelated to study vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events Including Intussusception</title>
        <description>All Serious adverse events (SAEs), including cases of intussusception, were recorded at all time points between first vaccination and last visit. An SAE was defined as any untoward medical occurrence that:&#xD;
Resulted in death,&#xD;
Was life threatening,&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization,&#xD;
Resulted in persistent or significant disability / incapacity,&#xD;
Was a congenital anomaly or a birth defect,&#xD;
Medically important event&#xD;
Investigator-confirmed cases of intussusception also qualified as an SAE in this study. Intussusception is the infolding (telescoping) of one segment of the intestine within another, usually resulting in a blockage of the intestine.</description>
        <time_frame>From first vaccination through 28 days after the last vaccination; 85 days</time_frame>
        <population>Safety population, as treated</population>
        <group_list>
          <group group_id="O1">
            <title>ROTAVIN Liquid Formulation</title>
            <description>Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
          <group group_id="O2">
            <title>ROTAVIN-M1 Frozen Formulation</title>
            <description>Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events Including Intussusception</title>
          <description>All Serious adverse events (SAEs), including cases of intussusception, were recorded at all time points between first vaccination and last visit. An SAE was defined as any untoward medical occurrence that:&#xD;
Resulted in death,&#xD;
Was life threatening,&#xD;
Required inpatient hospitalization or prolongation of existing hospitalization,&#xD;
Resulted in persistent or significant disability / incapacity,&#xD;
Was a congenital anomaly or a birth defect,&#xD;
Medically important event&#xD;
Investigator-confirmed cases of intussusception also qualified as an SAE in this study. Intussusception is the infolding (telescoping) of one segment of the intestine within another, usually resulting in a blockage of the intestine.</description>
          <population>Safety population, as treated</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="551"/>
                <count group_id="O2" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs related to study vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs unrelated to study vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intussusception</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events and mortality are reported from the first vaccination date until 28 days after last dose; 85 days. Other adverse events are reported up to 28 days after each dose (Days 1-28 and 57 to 85)</time_frame>
      <desc>Safety population, as treated One participant was randomized to ROTAVIN but instead received ROTAVIN-M1 and was therefore analyzed in the ROTAVIN-M1 group for safety based on the actual treatment received.</desc>
      <group_list>
        <group group_id="E1">
          <title>ROTAVIN Liquid Formulation</title>
          <description>Participants received two doses of ROTAVIN liquid formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
        </group>
        <group group_id="E2">
          <title>ROTAVIN-M1 Frozen Formulation</title>
          <description>Participants received two doses of ROTAVIN-M1 frozen formulation vaccine orally 8 weeks apart with the first dose administered at 60-91 days of age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="292" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>External ear inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="226" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Vaccination site inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Roseola</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Nasal cavity packing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="551"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="274"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nguyen Thuy Huong, Ph.D, Vice Director</name_or_title>
      <organization>POLYVAC</organization>
      <phone>+84 912514309</phone>
      <email>huong72us@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

